A Seminal Moment Arrives for Gene Therapy and Sickle Cell Disease – What’s Next?

Gbola Amusa, M.D., Partner, Chief Scientific Officer, Chardan (Moderator)
Samarth Kulkarni, Ph.D., CEO, CRISPR Therapeutics
Andrew Obenshain, CEO, bluebird bio